Bioxytran, Inc. (BIXT)
OTCMKTS · Delayed Price · Currency is USD
0.1621
-0.0117 (4.58%)
Apr 25, 2025, 4:00 PM EDT

Bioxytran Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Selling, General & Admin
2.112.651.162.20.72
Upgrade
Research & Development
0.111.150.982.010.54
Upgrade
Operating Expenses
2.233.812.144.211.27
Upgrade
Operating Income
-2.23-3.81-2.14-4.21-1.27
Upgrade
Interest Expense
-0.77-0.75-0.52-0.31-1.27
Upgrade
Other Non Operating Income (Expenses)
0.13----
Upgrade
EBT Excluding Unusual Items
-2.87-4.56-2.66-4.53-2.54
Upgrade
Other Unusual Items
0.49----
Upgrade
Pretax Income
-2.38-4.56-2.66-4.53-2.54
Upgrade
Earnings From Continuing Operations
-2.38-4.56-2.66-4.53-2.54
Upgrade
Minority Interest in Earnings
0.010.090.190.50.06
Upgrade
Net Income
-2.37-4.47-2.46-4.03-2.48
Upgrade
Net Income to Common
-2.37-4.47-2.46-4.03-2.48
Upgrade
Shares Outstanding (Basic)
13913411510694
Upgrade
Shares Outstanding (Diluted)
13913411510694
Upgrade
Shares Change (YoY)
3.45%16.13%8.57%13.07%9.78%
Upgrade
EPS (Basic)
-0.02-0.03-0.02-0.04-0.03
Upgrade
EPS (Diluted)
-0.02-0.03-0.02-0.04-0.03
Upgrade
EBITDA
-2.22-3.8-2.13--
Upgrade
D&A For EBITDA
0.010.010--
Upgrade
EBIT
-2.23-3.81-2.14-4.21-1.27
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.